MDxHealth receives US$1.1m EU grant
Will progress bladder cancer programme with Dutch partner NovioGendix
MDxHealth, a US molecular diagnostics company specialising in personalised cancer treatment, with partner NovioGendix in the Netherlands, has received a US$1.1m grant from Eurotrans-Bio to progress its bladder cancer research. Eurotrans-Bio is a European Commission initiative to foster research and development between companies and academia working in the biotech industry.
NovioGendix is a molecular diagnostics company spun out from Radboud University Nijmegen Medical Centre (RUNMC) in the Netherlands,
‘This grant provides MDxHealth and NovioGendix with the necessary resources to investigate further the unique biological indicators and patterns seen in bladder cancer derived from patient samples from the existing collaboration of NovioGendix with RUNMC,’ said Dr Jan Groen, ceo of MDxHealth, which is based in Raleigh, NC.
Over the next two years, MDxHealth and NovioGendix will use the funds to discover and validate tumour markers for the prediction of tumour progression into the muscle in developing invasive stage of bladder cancer using DNA methylation technologies, DNA sequencing and RNA-expression profiles on clinical samples collected from bladder cancer patients at the Urology Department of RUNMC. Such predictive markers will guide the treatment decisions for the more aggressive bladder tumours.
Bladder cancer is one of the most common cancers, with 60 to 80% of survivors experiencing recurrence of the disease.
